Grants for Exclusive - see details - Federal

The US Geological Survey is offering a funding opportunity to a CESU partner for research on wild horse population demography and ecology throughout the Western USA. This research will be comprised of a combination of field-based data collection and research, and data analyses through modelling techniques. The National Academies of Science (NAS) conducted a science review of the Bureau of Land Management (BLM) wild horse and burro program in 2013. An outcome of this NAS review was a number of recommendations for new research, identification of data gaps, and knowledge needs. The aim is to fill some of those data needs with collaborative research conducted jointly by USGS and CESU partner.

Fiscal Year 2024 Key Objectives Application proposals must include at least one of the following three objectives identified below. Proposals may contain more than one objective. As noted in Section 4, applicants must map their proposed activities and indicators measuring success to the objective(s) using the Activities/Indicators Tracker. If awarded, grantees will be required to use the FNS-908 Performance Progress Report to report on progress towards activities that align with the required objective(s) listed on the Activities/Indicators Tracker. Carefully considering proposed activities and indicators will prepare grantees for their performance progress reporting requirements if awarded. The project examples aligned with each objective listed below are only suggestions. A PTIG project may assist State agencies in making investments in systems to improve efficiency, provide excellent customer service, and meet Federal standards as they face unprecedented operational challenges. FNS welcomes other projects that support these objectives and encourages applicants to propose innovative ideas to solve both common and unique problems associated with SNAP application and eligibility processes. 1. Modernize SNAP customer service and client communication to improve accessibility, transparency, and responsiveness in processing applications and determining eligibility. 2. Improve administrative infrastructure and day-to-day SNAP operations in processing applications and determining eligibility. 3. Invest in technology and systems to encourage cross collaboration and cross enrollment between SNAP and other Federal, State, and local assistance programs. Please read the full announcement for additional details.

The "DoD Multiple Sclerosis, Clinical Trial Award" is a grant that funds the implementation of clinical trials aimed at significantly impacting the treatment or management of multiple sclerosis, ranging from small proof-of-concept trials to large-scale trials, with the expectation that the proposed trial will begin within 12 to 18 months after the award date.

The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but are not limited to: Studies moving from preclinical to clinical research and/or the reverse; or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or to improve diagnosis, prognosis, or treatment. Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics. Pilot clinical trials, where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes. New Studies improving clinical care of TSC encompassing the analysis of existing real-world clinical practice data to develop/improve guidelines for better outcomes in defined areas relevant to the FY24 TSCRP focus areas, include but are not limited to epilepsy surgery, tumor resection, reproductive health, perinatal surveillance and care, etc.Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for CTRA funding and should consider other FY24 TSCRP funding opportunities.

The FY24 RCRP RCDA supports the development of clinical or preclinical data sets and research resources that advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Major gaps in patient care of rare cancers include lack of communication and dissemination strategies for rare cancers research and clinical findings within communities; lack of therapeutics and mechanistic studies to inform treatment development; lack of research and clinical resources, including patient tissues, cell, and tumor models; and lack of infrastructure for sharing data and other resources.The intent of this funding opportunity is to develop research platforms that can share resources and knowledge pertaining to available preclinical or clinical research models, molecular pathways, and therapeutic approaches to facilitate collaboration and information sharing among stakeholders such as researchers, patients, caregivers, clinicians, and other members of the rare cancers community.Clinical or preclinical datasets should strive to integrate or develop the following research resources. This list is not all-inclusive: Building and sharing rare tumor biospecimen repository with clinical annotation Databases/banks for centralizing and sharing data for patient registries that can be accessed globally Centralizing and sharing research models and molecular data related to genomics/ transcriptomics/immune profiling/proteomics/metabolomics/methylomics/bioinformatics Generating a data/reagent/model exchange program where researchers can list resources that they are willing to share and are tagged with indications that may be relevant Platform to enable or leverage longitudinal studies of disease natural history and treatment response Development of novel methods and systems for collection, sharing, and analysis of data or biospecimensApplicants should include a well-formulated project design based on a strong scientific rationale and clearly articulate how the proposed resource platform or community development addresses an unmet need in rare cancers research. Applicants should explain the advantage of their approach to developing resources or community versus standard methodologies, techniques, or scopes. A clear plan for collaboration and data sharing needs to be demonstrated. It is critical to demonstrate how the outcome of the proposed project can benefit type(s) or sub-type(s) of rare cancers. It is encouraged for the research platform/resource to have an effect on multiple types or sub-types of rare cancers.Key Elements of the Resource and Community Development Award are as follows: Impact: Outcomes of the RCDA must have potential for major impact on an unmet need in rare cancers research. A resource, as developed in the proposed research, should aim forDOD FY24 Rare Cancers Resource and Community Development Award 5long-term anticipated advantages toward greatly improving outcomes for people with rare cancers. Patient Advocate Partnership: Applications to the RCDA funding opportunity are required to include patient advocates who are involved with patient advocacy organization(s). The research team must include at least two rare cancers patient advocates who will be early and integral partners throughout the planning and implementation of the research project. Patient advocates should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, and not limited to attending seminars and semi-annual meetings. The patient advocates must be individuals who have been directly impacted by a rare cancer either by being diagnosed themselves or as a caretaker/family member of a patient, and they should be active in a cancer advocacy organization or within a support group focused on their rare cancer. Their role should be focused on providing objective input on the research and its potential impact for individuals with or at risk for a rare cancer. The patient advocates should have a high level of understanding of current rare cancers research. Preliminary Data: Due to the developmental nature of this award, preliminary data are not required but may be included, if available, to address the feasibility of the resource to be developed. Whether or not preliminary data are included, applications must apply solid scientific rationale and logical reasoning based on existing knowledge to the development of the proposed product. Clinical Research: Research involving human subject use is permitted under this mechanism but is restricted to studies without clinical trials. Clinical trials will not be supported. Applications focused on clinical research should demonstrate how the study will leverage clinical information to address knowledge gaps in the development of platforms that can be utilized for sharing data and tissue, the development of clinical annotation datasets, process development, and/or infrastructure development. Applied Research: Preclinical studies utilizing or creating animal models to further research into rare cancers may be supported by this funding opportunity. The RCDA is intended to support projects that will have the potential to move beyond the realm of basic research, with results that may impact clinical research or patient outcomes. Community Building: A plan describing how the rare cancers stakeholder community will be built/enhanced and the communitys involvement with developing the resource platform is required. It is also important to justify how the community is essential for the development and sustainment of the resource platform. Dissemination: A Dissemination Plan is required. The plan should describe the means by which the fully developed resource platform will be made easily available to the scientific and/or clinical community. Dissemination of resource platform will play a major role by not only educating the rare cancer community about the recent progress, but also help to develop an informational network.DOD FY24 Rare Cancers Resource and Community Development Award 6 Sustainment: A plan that outlines the sustainability of the resource in the future is required. The plan should detail the types of rare cancers that are less studied in the collaborations and the resources to be gathered, annotated, and sustained. Additional expansion and feasibility plans should be included. It is important to demonstrate how the outcomes of the current award will be continued and eventually will help the rare care cancer community, beyond the award period.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP priorities.Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for women's health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.

The IDA promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. The following are important aspects of the IDA: Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (to the next logical step) is not considered innovative. Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are required. New-to-the-Field Investigator (NFI): The FY24 TSCRP IDA mechanism encourages applications from investigators in the early stages of their TSC research career. The NFI Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into TSC research. Applications to the NFI Option will compete separately from Established Investigators submitting to the regular IDA. PIs applying under the NFI category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in TSC research and/or possessing other relevant expertise as demonstrated by a record of funding and publications. See Attachment 8: Eligibility Statement.

The "DoD Rare Cancers, Idea Development Award" is a grant aimed at supporting early-stage research ideas with high potential impact, which could lead to significant advancements in the diagnosis, treatment, and improved health outcomes for individuals suffering from rare cancers, with a particular focus on innovative research involving nuclear medicine, women's health, and adherence to rigorous study design standards.

The "DoD Multiple Sclerosis, Exploration - Hypothesis Development Award" is a grant that supports the exploration of innovative, high-risk concepts in MS research, with the aim of laying the groundwork for future scientific investigation, and it particularly encourages applications from new investigators in the early stages of their careers.

The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.The following are important aspects of the EHDA: Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism. Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative: Explores a novel idea and/or research question in TSC research and/or patient care. Uses or develops novel methods or technologies to address a question in TSC research and/or patient care. Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended.

The FY24 RCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. The Concept Award is not intended to support an incremental progression of an already established research project; instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not required. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of rare cancers or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i., Full Application Submission Type, for more information.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs, and other federal government agencies are highly encouraged.DOD FY24 Rare Cancers Concept Award 5These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

The Mississippi Delta is a historically and culturally rich region of the United States. The architecture, French, Spanish, British, and German, is as diverse as the people whose origins are European, Native American, Spanish, African, and more. But for all its cultural wealth, there is a poverty of health and healthcare in the region. Residents of the 18-county region contend with persistent poor health outcomes compounded by challenges to attaining preventive services and care, poor quality of care, and stagnant opportunity structures, particularly as it relates to cardiovascular disease (CVD).Roughly 1 in 10 (9.9% 28.6 million) adults in the US have at least 1 type of CVD, including coronary heart disease, heart failure, or stroke. This number excludes hypertension, a risk factor for and cause of CVD but not a type of CVD. However, hypertension or high blood pressure is a critical risk factor for stroke. An estimated 120 million American adults (48.1%) have it, most (3 in 4) dont have it controlled, and 1 in 5 adults is unaware they have hypertension.In 2012 CVD, particularly heart disease, was the leading cause of death in the Delta (244.4 deaths per 100,000). The regions residents experience age-adjusted death rates due to heart disease, stroke, and other CVDs that are considerably higher than national rates and the rest of Mississippi. According to the 2018 Cardiovascular Health Examination Survey (CHES) in the Mississippi Delta, the adjusted overall prevalence of hypertension among adults in the region 18 and older was 42.8%.The persistence of these outcomes in the Delta is attributable to modifiable CVD conditions and risk factors, such as high blood pressure, high cholesterol, coronary heart disease, COPD, chronic kidney disease, diabetes, and stroke. To sufficiently address these conditions, interventions must include evidence-based and practice-based approaches that are innovative and tailored to the unique challenges and strengths of the 18-county MS Delta Region. These interventions are needed in strategies that are focused on health systems, team-based care, and linkages to community resources and clinical services that address the social conditions that contribute to the prevalence of CVD in the MS Delta Region. This cooperative agreement builds from lessons learned from previous iterations. It focuses on policy, systems, and environmental changes that impact clinical and community settings and lifestyle changes that reduce uncontrolled blood pressure and CVD within the MS Delta Region.

The Bureau of Counterterrorism (CT) of the U.S. Department of State announces an open competition for organizations to submit applications to host a one-week border security exercise in Coastal West Africa (CWA).

Although the pelagic ocean is the largest ecosystem on earth, it remains poorly characterized and understood due to its vast size and three-dimensional, highly dynamic nature (e.g., Perelman et al. 2021). Most oceanographic programs concentrate upon the surface ocean because plankton and larval fish are concentrated there. Very little of the water column below the epipelagic (0200 m) has been described in any detail (Netburn 2018). However, we know that important processes occur throughout that water column, such as the biological pump (Passow and Carlson 2012), diel vertical migration (Sutton 2013, Kelly et al. 2019), other mechanisms for connectivity (Sutton 2013), and food web dynamics (Choy et al. 2017). As industries move to deeper waters of the OCS, it is imperative to learn more about potential impacts to these habitats, specifically sites of commercial interest. Water column information can be collected by traditional oceanographic equipment, especially when supplemented by new techniques and technology. In addition to physical and chemical profiles of the water column, Conductivity-Temperature-Depth (CTD) rosette casts can collect water samples to evaluate the biological community through eDNA sampling. Cameras can also be integrated onto CTD rosettes to help image these pelagic environments for which the deeper habitats are rarely visualized. This study is intended to fund the integration of a complementary water column component into planned marine mineral and offshore wind-related research cruises in locations of potential commercial interest. There are two cost-effective near-term opportunities for at-sea data collection to support the proposed study objectives in the fall of 2024. One is a planned August 26 September 16 NOAA-led benthic habitats AUV survey on NOAA Ship Bell M. Shimada out of Newport, Oregon that is focused on areas of interest for offshore wind in northern California and southern Oregon. The second is a September 10 October 07 USGS-led multibeam and box core cruise on the R/V Kilo Moana out of Honolulu, Hawaii that will assess the abundance and composition of abyssal manganese nodules at the southern extreme of the OCS south of Hawaii. There appear to be several substantive outyear opportunities in 2025 and beyond to add a mid-water component to anticipated NOAA cruises in areas of interest for both offshore wind and critical minerals. BOEM will work with the award recipient to secure sample collection opportunities on select outyear opportunities. The scope of water column operations on each cruise will be designed in consultation with cruise Chief Scientists to address the highest priority mid-water environmental information needs while taking into account any pre-existing science plans and available planning horizon. For example, optical sensors (e.g., high-definition cameras, shadowgraphs) could be deployed when primary science operations are done for the day, or a smaller system could be integrated onto a CTD rosette to simultaneously collect imagery without needing dedicated wire-time. Data from the at-sea efforts will contribute significantly to baseline knowledge of pelagic systems that are highly dynamic and difficult to study. With industries moving into deeper waters further offshore, these water column data are necessary to understand environmental conditions and associated natural variation. For example, baseline environmental data can improve our understanding of environmental risks and potential impacts of floating offshore wind, such as changes in organism behavior and displacement (Maxwell et al. 2022). Additionally, current seabed mining technologies are expected to produce sediment plumes with unknown environmental impacts (Gollner et al. 2017, Gillard et al. 2019). Baseline data for these water column habitats are thus critical for identifying the resources that may be impacted and assessing what those impacts are likely to be.The proposed study will address the following objectives.Develop species inventories throughout the water column in areas of potential commercial interest for floating offshore wind and critical minerals, particularly abyssal manganese nodulesAssess other recent/ongoing scientific programs that can provide relevant data and meaningfully support the study objectives [e.g., California Current Ecosystem (CCE) Long-Term Ecological Research (LTER)] Explain the regional distribution of organisms relative to the physical and chemical oceanographic conditions Provide recommendations for a cost-effective and high-value sampling and sensor package or module(s) that can be easily integrated as a mid-water add-on to future research cruises. Some of the key questions to be addressed are:What is the pelagic community structure in current and potential regions of interest for offshore wind development and abyssal nodules in the Pacific OCS?What are the physical and chemical drivers in each region, and how do they relate to the pelagic community structure?What is a relatively simple and cost-effective standard midwater science component add-on that could provide high value to future deepwater Pacific research efforts?

This Program Announcement is issued under the provisions of section 104 of the Water Resources Research Act of 1984 (Public Law 98-242), as amended by Public Laws 101-397, 104-147, 106-374, 109-471, and 11758. Section 104 of the Water Resources Research Act directs the Secretary of the Interior to administer program grants to Institutes established under the provisions of section 104(a) of the Act. Water Resources Research Institutes have been established in each of the 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Guam. The Institute in Guam also serves the Federated States of Micronesia and the Commonwealth of the Northern Mariana Islands. The Institute in Hawaii also serves American Samoa. The addresses of the 54 Institutes are available at https://water.usgs.gov/wrri/index.php. Responsibility for administration of the Water Resources Research Act Program has been delegated to the U.S. Geological Survey (USGS).

This Program Announcement is issued under the provisions of section 104 of the Water Resources Research Act of 1984 (Public Law 98-242), as amended by Public Laws 101-397, 104-147, 106-374, 109-471, and 11758. Section 104 of the Water Resources Research Act directs the Secretary of the Interior to administer program grants to Institutes established under the provisions of section 104(a) of the Act. Water Resources Research Institutes have been established in each of the 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Guam. The Institute in Guam also serves the Federated States of Micronesia and the Commonwealth of the Northern Mariana Islands. The Institute in Hawaii also serves American Samoa. The addresses of the 54 Institutes are available at https://water.usgs.gov/wrri/index.php. Responsibility for administration of the Water Resources Research Act Program has been delegated to the U.S. Geological Survey (USGS).

This Program Announcement is issued under the provisions of section 104 of the Water Resources Research Act of 1984 (Public Law 98-242), as amended by Public Laws 101-397, 104-147, 106-374, 109-471, and 11758. Section 104 of the Water Resources Research Act directs the Secretary of the Interior to administer program grants to Institutes established under the provisions of section 104(a) of the Act. Water Resources Research Institutes have been established in each of the 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Guam. The Institute in Guam also serves the Federated States of Micronesia and the Commonwealth of the Northern Mariana Islands. The Institute in Hawaii also serves American Samoa. The addresses of the 54 Institutes are available at https://water.usgs.gov/wrri/index.php. Responsibility for administration of the Water Resources Research Act Program has been delegated to the U.S. Geological Survey (USGS).

The United States Embassy in Bosnia and Herzegovina (BiH), through the Office of Public Diplomacy Section (PDS), is pleased to announce a Notice of Funding Opportunity to design and implement the BOLD Academic Fellowship Program on Economic Development. PDS invites proposal submissions from U.S. public and private non-profit organizations and accredited U.S. post-secondary educational institutions (community colleges, liberal arts colleges, public and private universities) meeting the provisions described in Internal Revenue Code section 26 USC 501(c)(3) (see section III, Eligibility Information) to design and implement the BOLD (Balkanski Omladinski Lideri, Balkan Young Leaders) Academic Fellowship for BiH Student Leaders on Economic Development, pending the availability of Fiscal Year 2023/2024 Assistance to Europe, Eurasia and Central Asia (AEECA) funds.

The goal of USAID/Cambodias new five-year community tuberculosis (TB) activity is to accelerate TB case finding and case holding activities to maximize TB outcomes among Cambodians, including vulnerable populations such as Indigenous People. This Activity will build on USAIDs previous investments in community TB control, including the USAID Community Mobilization Initiatives to End Tuberculosis (COMMIT) activity, recommendations from the COMMITs mid-term evaluation, and lessons learned from stakeholders; and further contribute to the National TB Strategic Plan to End TB (2021-2030), World Health Organizations (WHO) End TB Strategy, and USAIDs Global TB Strategy 2023 - 2030. This Activity will focus on improving and streamlining the implementation of the End TB strategy at the community level while strengthening longer-term systems and capacity for: improving access to and demand for high quality TB services and advancing their integration within national health systems, creating an enabling private sector environment for TB control and the provision of TB services, and improving TB Management Information System (MIS) systems and data use, to provide better and more sustainable TB services.

You must download both the Application Instructions and the Application Package from Grants.gov. You must verify that the Assistance Listing Number and Assistance Listing Description on the first page of the Application Package, and the Funding Opportunity Title and the Funding Opportunity Number match the Program and NOFO to which you are applying.The Application Package contains the portable document forms (PDFs) available on Grants.gov, such as the SF-424 Family. The Instruction Download contains official copies of the NOFO and forms necessary for a complete application. The Instruction Download may include Microsoft Word files, Microsoft Excel files, and additional documents.An applicant demonstrating good cause may request a waiver from the requirement for electronic submission, for example, a lack of available Internet access in the geographic area in which your business offices are located. Lack of SAM registration or valid DUNS/UEI is not good cause. If you cannot submit your application electronically, you must ask in writing for a waiver of the electronic grant submission requirements. HUD will not grant a waiver if the Applicant fails to submit to HUD in writing or via email a request for a waiver at least 15 calendar days before the application deadline. If HUD grants a waiver, a paper application must be received before the deadline for this NOFO. To request a waiver, you must contact:

NOTE: Please refer to the "Related Documents" tab for the full text of the NOFO. FHWA highly recommends interested applicants "Subscribe" to this opportunity to allow Grants.gov to send notifications to those parties concerning changes or updates to this NOFO. NOFO Amendment 1 Summary (Posted 4/25/2024): The purpose of this amendment is to provide the link and updated date and time information for this NOFO's Informational Webinar. The webinar will be held on 5/2/2024 from 2:00PM - 3:00PM (Eastern), and can be accessed via the following link: https://usdot.zoomgov.com/j/1612256897?pwd=bGZmMHJEU2dUTWFIeFkzTG5LQmRMdz09 [END OF AMENDMENT 1 SUMMARY] Original NOFO Synopsis Summary (Posted 4/17/2024): The purpose of this NOFO is to solicit applications for the Highway Construction Training Program (HCTP) to award highway construction workforce development grants. The NOFO will result in the distribution of up to $4,226,871. The purposes of the HCTP as described in 23 U.S.C. 504(f) are to: 1) Develop, test, and review new curricula and education programs to train individuals at all levels of the transportation workforce; and 2) To implement the new curricula and education programs to provide for hands-on career opportunities to meet current and future needs. As further described in 23 U.S.C. 504(f)(2), in making grants, FHWA may consider the extent to which the project will: A) Develop new curricula or education program to meet the specific current or future needs of a segment of the transportation industry, States, or regions. B) Provide for practical experience and on-the-job training. C) Be oriented toward practitioners in the field rather than the support and growth of the research community. D) Provide for new curricula or programs that will provide training in areas other than engineering, such grants as business administration, economics, information technology, environmental science, and law. E) Provide programs or curricula that train professionals for work in the transportation field, such as construction materials, information technology, environmental science, urban planning, and industrial or emerging technology. F) Demonstrate the commitment of industry or a State DOT to the program.